

- complications of
 adrenal insufficiency, 1755
 cardiopulmonary, 1746, 1755
 coagulopathy, 1755
 encephalopathy, 1782
 hypoglycemia, 2433
 hypothermia, 478e-1
 hypovolemia, 298
 immunosuppression, 1755
 intracranial hemorrhage, 2584
 neurologic, 169, 1755
 renal, 1755, 1801, 1806t
 in critically ill patient, 1734
 definition of, 1751, 1751t
 diagnosis of, 1755–1756
 epidemiology of, 1752
 etiology of, 780t, 781, 1751, 1752t, 1756
 hemodynamic patterns in, 1762t
 in HIV infection, 1757t
 in IV drug user, 1757t
 pathophysiology of, **1753**
 coagulation factors in, 1753
 control mechanisms in, 1753–1754
 cytokines in, 1753
 endothelial injury in, 1754
 host mechanisms and, 1752–1753
 organ dysfunction in, 1754
 physiologic characteristics of, **1748t**
 postsplenectomy, 484, 1757t
 prevention of, 1759
 prognosis of, 1758–1759
 puerperal, 968
 refractory, 1751t
 severe, 1754
 treatment of, 780t, **1756**, 1757t
 antimicrobial agents, 1756, 1757t
 empirical, 780t
 general support, 1757–1758
 hemodynamic, respiratory, and metabolic support, 1757
 investigational, 1758
 removal of infection source, 1756–1757
 without clear focus, 780t, 781
- Septal panniculitis. *See* Erythema nodosum
 Septic arthritis. *See* Infectious (septic) arthritis
 Septic diskitis. *See* Osteomyelitis, vertebral
 Septic emboli
 in infective endocarditis, 76e-12f, 818, 818f
 retinal, 40e-4
- Septicemia
 deaths from, 6e-1t
 hemolysis in, 657t
 meningococcal. *See* Meningococemia
 plague, 1072
 respiratory alkalosis in, 324
- Septic thrombosis
 of cavernous sinus, 783, 906
 of superior sagittal sinus, 783, 905–906
- Septo-optic dysplasia, 2256
 Septum primum, 1520
 Septum secundum, 1520
 SERCA2a, 91e-4, 1503, 1515
 Serelaxin, 1509, 1510t
 Serine kinase receptors, 400e-1t, 400e-3f, 400e-4
 Serine metabolism disorders, 434e-2t
 SERMs. *See* Selective estrogen response modulators (SERMs)
- Serotonin (5-HT)
 action of, 444e-3t
 in carcinoid syndrome, 565
 clinical aspects of, 444e-3t
 in coordination of emesis, 103e-25
 laboratory evaluation of, 566
 in migraine, 2588
 pain and, 88f
 structure of, 444e-3t, 566f
 synthesis, secretion, and metabolism of, 560f, 561
- Serotonin (5-HT_{1B/1D}) agonists
 adverse effects of, 2591
 for migraine, 2590–2591, 2592t
 nasal, 2591, 2592t
 parenteral, 2591, 2592t
- Serotonin (5-HT₄) agonists
 for gastroparesis, 260, 260t
 for irritable bowel syndrome, 1970
- Serotonin (5-HT₃) antagonists
 adverse effects of, 261
 for irritable bowel syndrome, 1970
 for nausea and vomiting, 109, 260, 260t
- Serotonin norepinephrine reuptake inhibitors (SNRIs)
 adverse effects of, 2710t
 for dementia, 175
 for depression, 64, 2710t
 for PTSD, 471e-5
- Serotonin (5-HT₃) receptor antagonists
 for carcinoid syndrome, 565, 566–567
 for nausea and vomiting, 62, 103e-25
 structure of, 566f
- Serotonin release assay, 752
- Serotonin syndrome
 clinical features of, 473e-13t
 etiology of, 473e-13t, 2624
 mechanism of, 473e-13t
 with SSRIs, 2716
 treatment of, 473e-6, 473e-13t
- Serra Norte virus, 1309t
- Serratia* spp. infections, **1034**
 antibiotic resistance in, 1034
 in cancer patient, 486t
 clinical features of, 1034
 diagnosis of, 1034
 ecthyma gangrenosum, 369
 epidemiology of, 1025, 1034
 sinusitis, 226
 treatment of, 1034
- Sertoli-Leydig tumor, 594
- Sertraline
 adverse effects of, 2710t, 2716
 for depression, 64, 473, 2672, 2710t, 2712, 2716
 for obsessive-compulsive disorder, 2714
 for panic disorder, 2709
 for PTSD, 2712
- Serum albumin. *See* Albumin, serum
 Serum ascites-albumin gradient, 287
 Serum bilirubin. *See* Bilirubin, serum
 Serum-binding proteins, 400e-2
 Serum ferritin. *See* Ferritin, serum
 Serum proteins, electrophoresis of, 710–712, 712f
- Serum sickness
 with antivenom, 2737
 with ATG treatment, 667
 clinical features of, 377, 384t, 2193, 2737
 immunologic mechanisms of, 44, 2180
 pathogenesis of, 377
 treatment of, 667, 2737
 urticaria/angioedema in, 363, 363t, 2118
 urticaria-like eruptions in, 132t, 135
- Serum sickness–like illness, 363, 377, 2193
 Setting sun sign, 210
 Sevelamer, 1816, 2458
- Seven transmembrane GPCR family, 372e-16, 400e-3, 400e-3f
- Severe acute respiratory syndrome (SARS)
 as bioterrorism agent, 261e-9
 clinical features of, 1204
 diagnosis of, 772, 1204
 epidemiology of, 916, 1204
 genome sequence of, 772
 infection-control practices for, 1205
 pathogenesis of, 1204
 super-spreaders, 1204
 surveillance for, 1205
- Severe combined immunodeficiency (SCID)
 clinical features of, 375e-1, 2107
 diagnosis of, 2107–2108
 etiology of, 2108
 genetic considerations in, 372e-16
 HSCT in, 139e-2, 139e-5, 139e-5t
 T cell differentiation and, 2108f
 treatment of, 91e-1–2, 2108
- Severe congenital neutropenia (SCN), 375e-1, 2104, 2105f
- Severe fever with thrombocytopenia syndrome, 1309t, 1322
- Severity-of-illness (SOI) scoring systems, 1729, 1730t
- Sex chromosome(s), 426, 437
 Sex chromosome disorders, 2350t
 Klinefelter's syndrome. *See* Klinefelter's syndrome
 ovotesticular DSD, 2351t, 2353
 Turner's syndrome. *See* Turner's syndrome
 45,X/46,XY mosaicism (mixed gonadal dysgenesis), 2351t, 2352–2353
- Sex cord tumors, ovarian, 594
- Sex development
 components of, 2349, 2349f, 2352f
 disorders of. *See* Disorders of sex development (DSDs)
 genetic regulation of, 2350f
 Sex differences, 6e-1, 7e-1. *See also* Men's health; Women's health
- Sex headache, primary, 2597
- Sex hormone-binding globulin, 332, 2378, 2763t
- Sex-influenced trait, 437
- Sex-limited trait, 437
- Sex-reversal, 431t, 435, 437
- Sex therapy, 329–330
- Sexual abuse
 gonococcal infections in, 1006, 1008
 sexual dysfunction in adulthood following, 326, 330t
- Sexual arousal disorder, female, 330
- Sexual assault, 6e-5
- Sexual dysfunction
 alcohol use and, 2725
 cocaine use and, 469e-1
 female, 330–331, 330t, 2427
 incidence of, 324
 male, 7e-1–2. *See also* Erectile dysfunction (ED)
 in MS, 2663, 2672
 SSRI-related, 2716
- Sexually transmitted infections (STIs), **869**. *See also specific infections*
 cervical cancer and, 594
 in children, 1006
 classification of, 869–870
 dysuria in, 60e-1
 epidemiology of, 869–870, 869t
 etiology of, 869t, 870t
 global considerations in, 869, 879
 HIV transmission and, 1221
 partner notification in, 883
 in pregnancy, 50
 prevention and control of, 882–883, 882f
 risk assessment for, 870, 871t
 screening for, 882–883
 in travelers, 797
- Sexual pain disorder, 330
- Sexual response, physiology of
 female, 330
 male, 324–325, 325f
- Sézary's syndrome, 81e-10f, 354, 391, 707
- SF1 (steroidogenic factor 1), 2310, 2349
- SFI gene mutations
 in disorders of sex development, 2349, 2353, 2354t
 in hypogonadotropic hypogonadism, 2364t
- SF3B1 gene mutations, 135e-6
- S genes, of HBV, 2005–2006, 2005f
- SH3TC2 gene mutations, 444e-1
- Shah-Waardenburg syndrome, 359, 431t
- Shaking rigors, 478e-3
- Shannon index, 86e-4
- Shapiro syndrome, 478e-1
- Shared epitope, 2139
- Shawl sign, 2195
- SHBG gene mutations, 2360
- Sheehan's syndrome, 2257
- Shellfish poisoning
 amnestic (domoic acid intoxication), 2547–2548, 2743
 diarrhetic, 2741–2742
 paralytic, 2742
- Shewanella* spp. infections, 183e-2t, 183e-3
- Shift cells, 396, 396f